The global sequencing consumables market size was estimated at USD 6.91 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 22.8% from 2024 to 2030. Continuous advancement in sequencing technologies and growing emphasis on genomics research are the prime factors driving the overall growth of the global sequencing consumables industry. As sequencing technologies evolve, they become more efficient, accurate, and capable of handling larger volumes of data that drives the increased adoption of sequencing in various fields, including genomics and personalized medicine.
With such high demand, newer sequencing platforms require specialized consumables that are compatible with their unique processes. This creates opportunities for consumable manufacturers to develop and provide customized products that cater to the specific needs of these cutting-edge technologies. For instance, third-generation sequencing technologies represent the latest advancements in DNA profiling, offering new approaches that overcome the limitations of previous technologies. In addition, one of the most widely used third-generation sequencing techniques is nanopore sequencing.
The COVID-19 pandemic had a profound impact on the sequencing consumable sector, primarily due to the surging demand for testing and research. As a result, the need for sequencing consumables has significantly risen. Consequently, the market has witnessed shortages in specific consumables and supplies, with manufacturers facing challenges in meeting this heightened demand. This situation has created a window of opportunity for consumable manufacturers to innovate and offer tailored products that address the specific requirements of these advanced technologies, thereby playing a pivotal role in driving the overall growth of the market.
The rising prevalence of genetic diseases significantly drives the growth of the market. As genetic diseases become more prevalent, there is an increased need for genetic testing, diagnosis, as well as profiling technologies. As per a WHO r eport published in 2021, 10 out of every 1000 people are affected by single-gene diseases. This statistic indicates that there are approximately 70 to 80 million individuals living with various types of genetic diseases worldwide. Thus, the growing prevalence of genetic disorders and the availability of genetic testing services have led to an increased demand for sequencing consumables, thereby contributing to the overall market growth.
Based on end-use, the market is segmented into pharmaceutical and biotechnology companies, hospitals and laboratories, academic research institutes, and others. The hospitals and laboratories segment dominated the market in 2023 with a revenue share of 36.5% due to their crucial role in both clinical diagnostics and research applications. Hospitals utilize sequencing consumables for various clinical purposes, such as cancer diagnostics, infectious disease detection, and personalized medicine, where precise genetic information is vital for patient care.
Laboratories, including clinical diagnostic labs and research institutions, heavily rely on sequencing consumables for genomics research, disease investigation, and drug development. The New York Genome Center is dedicated to pushing forward the progress and utilization of innovative genomic technologies. Their faculty, staff scientists, and collaborative research partners are collectively engaged in creating novel technologies that facilitate a deeper comprehension of the genome and its various functions. Hence, the increasing integration of genomics into healthcare practices plays a pivotal role in establishing the dominance of this segment.
In addition, thepharmaceutical and biotechnology companies segment is anticipated to register the fastest CAGR of 25.3% over the forecast period due to their expanding adoption of genomics technologies for drug discovery, development, and precision medicine initiatives. Sequencing consumables play a crucial role in aiding these companies in the identification of drug targets, conducting biomarker research, and evaluating the safety and effectiveness of pharmaceutical compounds. This is expected to drive the growth of the pharmaceutical and biotechnology segment during the forecast period.
North America dominated the market with a revenue share of 51.2% in 2023. The regional market is driven by the presence of multiple clinical laboratories that employ NGS to provide genetic testing services. Substantial government investments in genomics research also contribute to the market growth in the region. In July 2022, Genome Canada announced funding of USD 1.5 million to the Bison Integrated Genomics (BIG) project, which aims to protect the threatened Canadian bison population. Asia Pacific is expected to show a lucrative CAGR of 24.3% over the forecast period. This can be attributed to the development of healthcare, R&D, and clinical development frameworks in emerging economies such as India and Australia.
Based on product, kits dominated the market with a revenue share of over 80.0% in 2023. The dominance of the segment is due to their convenience, efficiency, and comprehensive nature. By providing pre-optimized and quality-controlled components, kits reduce the risk of errors and variability, making them attractive to users seeking reliable and standardized results. Hence, the ease of use and reduced hands-on time associated with kits make them particularly well-suited for high-throughput sequencing. Key players are investing in the development of innovative kits to meet their heightened demand in the market. In December 2021, Singular Genomics Systems, Inc. launched its next-generation sequencing (NGS) G4 kit, which includes multiple cycle configurations in each consumable kit, providing greater flexibility for various applications.
The reagents segment is anticipated to grow at a CAGR of 20.2% from 2023 to 2030. Reagents play a fundamental role in DNA and RNA profiling, serving as crucial elements in sample preparation, amplification, and profiling procedures. With the continuous advancement and diversification of profiling technologies, there is an increasing demand for specialized reagents customized for specific applications, like library preparation and target enrichment. Sequencing consumable reagents produce various layers of genomic data vital for drug development, ranging from studying genomic alterations to profiling the transcriptome. This versatility is anticipated to drive substantial growth in this market segment.
Based on the platform, the second-generation sequencing consumables segment dominated the segment with a revenue share of over 66.0% in 2023. Second-generation sequencing consumables are known for their high-throughput capabilities, accuracy, and cost-effectiveness, making them suitable for a wide range of projects. Additionally, the ability to reduce the risk of artifacts introduced by cloning or PCR amplification by analyzing individual molecules at a time further contributes to the dominance of the segment.
The third-generation sequencing consumables segment is anticipated to grow at the fastest CAGR of 43.9% from 2024 to 2030. Third-generation sequencing technology is one of the most advanced technologies that offers longer read time which helps to alleviate numerous computational challenges surrounding genome assembly, and transcript reconstruction, thereby contributing to the growing demand of the segment. Furthermore, this technology offers faster turnaround times than second-generation sequencing, making it a preferable choice over other technologies.
Based on application, the cancer diagnostics segment dominated the market in 2023 with a revenue share of 26.4% due to the need for precise and personalized cancer treatments. The high worldwide prevalence of cancerand the increasing adoption of sequencing technologies in oncology have propelled the demand for sequencing consumables. Numerous companies and research institutions are actively developing sequencing consumables for cancer diagnostics. These consumables are designed to support a wide range of applications in cancer research, including the identification of genetic mutations, biomarker discovery, and monitoring of disease progression. For instance, Illumina, Inc. offers TruSight Oncology 500 Consumables that facilitate comprehensive genomic profiling of tumor samples.
The pharmacogenomics segment is projected to exhibit a lucrative CAGR of 23.4% over the forecast period due to its significant ability to explore how people’s genetic makeup impacts their reactions to medications. By analyzing a patient's genetic profile, pharmacogenomics aims to identify the most effective and safe drugs for a particular individual. Thus,as pharmacogenomics gains prominence in clinical practice, the demand for sequencing consumables, including reagents, library preparation kits, and target enrichment solutions, is expected to increase. This heightened demand is set to be a driving force for the growth of this segment during the forecast period.
Key players in the market are launching various strategic initiatives to strengthen and retain their presence. For instance, in October 2023, The National Human Genome Research Institute (NHGRI) predominantly supported genomic medicine research by funding multi-disciplinary consortia and investigator-initiated research projects. This funding opportunity announcement (FOA) is designed to stimulate the submission of Small Business Innovation Research (SBIR) grant applications from small businesses that aim to advance genomic medicine research.
Report Attribute |
Details |
Market size value in 2024 |
USD 8.41 billion |
Revenue forecast in 2030 |
USD 28.82 billion |
Growth rate |
CAGR of 22.8% from 2024 to 2030 |
Base year for estimation |
2023 |
Historical data |
2018 - 2022 |
Forecast period |
2024 - 2030 |
Quantitative units |
Revenue in USD million/billion, and CAGR from 2024 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, trends |
Segments covered |
Product, platform, application, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait |
Key companies profiled |
Hoffmann-La Roche Ltd.; QIAGEN; Agilent Technologies; Millipore Sigma; Takara Bio Inc.; Beckman Coulter, Inc.; Eurofins Genomics; Oxford Nanopore Technologies Ltd.; Thermo Fisher Scientific, Inc.; BGI Genomics |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global sequencing consumables market report based on product, platform, application, end-use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Kits
DNA Library Preparation
RNA Library Preparation
Target Enrichment
Library Quantification
Purification & Quality Control
Others
Reagents
Sample Prep
Library Preparation And Amplification
Sequencing
Accessories
Collection Tubes
Plates
Others
Platform Outlook (Revenue, USD Million, 2018 - 2030)
1st Generation Sequencing Consumables
2nd Generation Sequencing Consumables
3rd Generation Sequencing Consumables
Application Outlook (Revenue, USD Million, 2018 - 2030)
Cancer Diagnostics
Infectious Disease Diagnostics
Reproductive Health Diagnostics
Pharmacogenomics
Agrigenomics
Others
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical And Biotechnology Companies
Hospitals And Laboratories
Academic Research Institutes
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
b. The global sequencing consumables market size was estimated at USD 6.91 billion in 2023 and is expected to reach USD 8.41 billion in 2024.
b. The global sequencing consumables market is expected to grow at a compound annual growth rate of 22.8% from 2024 to 2030 to reach USD 28.82 billion by 2030.
b. North America dominated the sequencing consumables market with a share of 51.25% in 2023. This is attributable to the large number of research institutes and biotechnology companies using sequencing consumables within the region
b. Some key players operating in the sequencing consumables market include Hoffmann-La Roche Ltd., QIAGEN, Agilent Technologies, Millipore Sigma, Takara Bio Inc., Beckman Coulter, Inc, Eurofins Genomics, Oxford Nanopore Technologies Ltd, Thermo Fisher Scientific, Inc, BGI Genomics
b. Key factors that are driving the market growth include continuous advancement in sequencing technologies and growing emphasis on genomics research across the globe
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."